Hemophilia Clinical and Cost Management Strategies for Managed Care and Specialty Pharmacy

Track 1: Integrating the Latest Clinical Recommendations to Improve the Quality of Care
Track 2: Hemophilia Cost Management and Care Coordination Strategies

• Release Date: January 25, 2018
• Expiration Date: July 31, 2019
• Estimated Time to Complete Activity: 1.5 hours per track
• Compatible with all modern browsers and mobile devices

Expert Faculty

Jennifer Maahs, RN, PNP, MSN Nurse Practitioner Indiana Hemophilia and Thrombosis Center Click here for biography Edmund Pezalla, MD, MPH CEO Enlightenment Bioconsult, LLC Click here for biography Vanita Pindolia, PharmD, BCPS, MBA Vice President, Ambulatory Clinical Pharmacy Programs Henry Ford Health System/Health Alliance Plan of Michigan Click here for biography Steven W. Pipe, MD Director, Division of Pediatric Hematology and Oncology Pediatric Medical Director, Hemophilia and Coagulation Disorders Program University of Michigan Click here for biography Michael Zeglinski, RPh Senior Vice President, Specialty Pharmacy OptumRx®/BriovaRx® Click here for biography

Target Audience

• Medical directors and pharmacy directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for hemophilia patients including: physicians, pharmacists, nurses, case managers, and social workers

Statement of Need/Program Overview
Due to the advent of new and more costly treatment modalities, the management of pediatric and adult hemophilia patients has become more complex for physicians, nurses, case managers, payers, specialty pharmacies, home health providers, and families/caregivers. In the absence of a coordinated educational effort, the full benefits of care coordination and the comprehensive care model have not yet been achieved.

This educational initiative will provide managed care and specialty pharmacy professionals with the latest information, presented by multi-disciplinary expert faculty, on the management of pediatric and adult hemophilia patients in health plan, specialty pharmacy, and other managed care settings. Represented on the faculty panel are Hemophilia Clinical Experts, Managed Care Experts, and Specialty Pharmacy Experts.

Educational Objectives
After completing this activity, the participant should be better able to:

• Describe current and evolving strategies used by managed care organizations (MCOs) and specialty pharmacy providers to facilitate high quality care for members with hemophilia
• Cite the most recent clinical recommendations for the treatment of patients with hemophilia, including prophylactic factor replacement and the role of emerging agents
• Explain hemophilia-related complications associated with inhibitor development and its significant clinical and economic consequences
• Identify processes for MCOs and specialty pharmacy providers to improve communications with HTCs
• Apply methods to enable optimal cost management of factor replacement therapy to be realized by multiple hemophilia stakeholders including MCOs and specialty pharmacy providers

ACCREDITATION

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER), National Hemophilia Foundation, and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates these enduring materials for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

• Track 1: 1.5 AMA PRA Category 1 Credits™
• Track 2: 1.5 AMA PRA Category 1 Credits™

Pharmacist Continuing Education

	Accreditation Statement Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 3.0 contact hours (0.30 CEUs) of the Accreditation Council for Pharmacy Education.

Credit Designation (Tracks 1 & 2)
Medical Education Resources designates these continuing education activities for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Track 1: UAN: 0816-9999-17-095-H01-P, 1.5 contact hours. This activity is certified as Knowledge-based CPE.

Track 2: UAN: 0816-9999-17-096-H01-P, 1.5 contact hours. This activity is certified as Knowledge-based CPE.

Nursing Continuing Education

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Medical Education Resources is accredited as a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Credit Designation (Tracks 1 & 2)
These educational activities for 3.0 contact hours are provided by Medical Education Resources.

• Track 1: Integrating the Latest Clinical Recommendations to Improve the Quality of Care – 1.5 contact hours
• Track 2: Hemophilia Cost Management and Care Coordination Strategies – 1.5 contact hours

Case Manager Credit
CCMC Approval Statement for certificate of completion:
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM^® board certified case managers.

Track 1: The course is approved for 1.5 CE contact hour(s). Activity code: 100028394 Approval Number: 170003402

Track 2: The course is approved for 1.5 CE contact hour(s). Activity code: 100028393 Approval Number: 170003401

To claim these CEs, log into your CE Center account at www.ccmcertification.org.

Social Worker Credit
This program is Approved by the National Association of Social Workers for 3.0 continuing education contact hours.
Track 1: The course is approved for 1.5 continuing education contact hours. Approval # 886699596-5143
Track 2: The course is approved for 1.5 continuing education contact hours. Approval # 886699596-6662

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, the National Hemophilia Foundation and/or Novo Nordisk, Inc., Shire, Bioverativ, and Bayer Pharmaceuticals HealthCare. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period January 25, 2018 through July 31, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 70% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.